GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery

Group Sales Down 3% As UK Vaccine Supply Deal Is Struck

GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.  

Coins
Sales take a dip at GSK • Source: Shutterstock

Sales by GlaxoSmithKline plc’s vaccines business declined by 29% in the second quarter of 2020, as COVID-19 pandemic lockdown measures limited visits to physicians but there were initial signs of a recovery in vaccination rates, reported CEO Emma Walmsley as the results were announced on 29 July. 

Although GSK is maintaining its 2020 financial guidance (a decline in adjusted EPS of 1% to 4% at constant exchange...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.